News | Ablation Systems | May 16, 2019

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study

Researchers report QDot Micro radiofrequency ablation catheter demonstrates safety and achieves pulmonary vein isolation with shorter procedure and fluoroscopy times

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter demonstrated safety and efficacy in achieving pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation (AF).

Procedure and fluoroscopy times were also reported to be shorter than ablation with conventional catheters. Reducing use of fluoroscopy alleviates the burden of lead for physicians and staff, and reduces exposure to radiation for patients.

These findings from QDOT-FAST, the first in-human multicenter study of the device, were published in JACC: Clinical Electrophysiology and presented at Heart Rhythm 2019, the Heart Rhythm Society's (HRS) 40th Annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco. Results were presented by Vivek Y. Reddy, M.D., director of cardiac arrhythmia services for The Mount Sinai Hospital and the Mount Sinai Health System and the Helmsley Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai in New York. The study was funded by Biosense Webster.

QDOT MICRO, a novel catheter that facilitates high power-short duration radiofrequency (RF) ablation and is only available for investigational use in the U.S. and Europe, is the first irrigated contact force catheter to deliver up to 90 watts of RF power in up to four seconds in a temperature-controlled ablation mode. The current practice of RF ablation with irrigated catheters involves the delivery of moderate power (20 to 40 watts) for a relatively long duration (20 to 40 seconds).[1]

In the three-month multicenter prospective study, researchers reported pulmonary vein isolation (PVI) was successful in all 52 paroxysmal AF patients treated with a total average procedure time of 105.2 minutes. PVI was achieved in 44.3 minutes, and most fluoroscopy times were between 2.5 and 5.7 minutes. Primary adverse events occurred in 3.8 percent of patients (1 pseudoaneurysm, 1 asymptomatic thromboembolism) and one non-serious adverse event (esophageal ulcer) was device/procedure-related.

“The results are very promising and may lead to better patient outcomes and improved procedural efficiencies, including short overall procedure and fluoroscopy times,” said Reddy, a study co-author. “Additional prospective studies are needed to assess for the durability of the lesion set and long-term freedom from recurrent atrial arrhythmias.”

In addition to the QDOT-FAST Study, Biosense Webster is also currently enrolling and treating patients in a U.S. Investigational Device Exemption (IDE) study of QDot Micro.

An estimated 33 million people worldwide have been diagnosed with AF and its prevalence is projected to increase significantly as the population ages.[2] Approximately 70 percent of patients with AF are between the ages of 65 and 85.[3]

For more information: www.biosensewebster.com

 

References

[1] http://electrophysiology.onlinejacc.org/content/early/2018/02/02/j.jacep.2017.11.018

[2] European Heart Journal, Volume 37, Issue 38, 7 October 2016, Pages 2893–2962, https://doi.org/10.1093/eurheartj/ehw210

[3] Amin A, Houmsse A, Ishola A, Tyler J, Houmsse M. The current approach of atrial fibrillation management. Avicenna J Med. 2016 Jan-Mar; 6(1): 8–16.

Related Content

News | Ablation Systems

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News | Ablation Systems

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
News | Ablation Systems

May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an ...

Home May 14, 2019
Home
Subscribe Now